Sabag Mark sold 44,710 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD at $44.14 for −$1.97M on Nov 12, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See "Remarks"
See "Remarks"
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,973,544.11Shares × reported price
Shares traded
44,710Ordinary Shares
Price per share
$44.14Reported price. Read footnotes for ranges.
% of reported position traded
35.63%This security and ownership context
Holdings after
80,760Direct
Trade date
Nov 12, 2026Sell
Filed
Nov 12, 2026, 4:12 PM ET0-day reporting delay
Accession
0001193125-26-458410Code S · Transaction 398835
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 125,470 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Option exercise44,710$34.90$1,560,379Trade 398834
Nov 12, 2026Option exercise44,710$0.00$0Trade 398836
3 transaction rows in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −5.5%1w ago −7%1d ago −0.9%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.10 to $44.29, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.